MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial carcinoma. However, the response rate is only 40–65%. This study investigated the anti-tumor effect and underlying mechanisms of the combination of cisplatin and the NEDD8-activating enzyme inhibitor MLN4924 in h...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655337/ |